IBRX News and Press, ImmunityBio Inc. From 03/29/23

2023-03-29 11:28:16 ET With so much volatility in the stock market today, you may consider penny stocks an option. These stocks are typically priced under $5 and are known for extreme price fluctuations. They are also known for their potential for high returns. With that, they come with sig...

2023-03-27 12:43:37 ET Summary ImmunityBio, Inc. has a May 23 PDUFA for Anktiva with superb data in NMIBC. A recent small $50mn raise broke the stock's back. Most of the huge $700+mn debt is owed to billionaire Dr. Patrick Soon-Shiong. ImmunityBio, Inc. ( IBRX ) ...

2023-03-21 12:48:20 ET Gainers: U.S. Xpress Enterprises ( USX ) +299% . Dermata Therapeutics ( DRMA ) +81% . First Republic Bank ( FRC ) +40% . Starbox ( STBX ) +36% . BigBear.ai ( BBAI ) +31% . Envirotech Vehicles ( EVTV ...

2023-03-21 10:03:51 ET Gainers: ImmunityBio ( IBRX ) +21% . NuCana ( NCNA ) +16% . Seres Therapeutics ( MCRB ) +14% . SCYNEXIS ( SCYX ) +13% . Corbus Pharmaceuticals ( CRBP ) +12% . Losers: Altimmune ( ALT ) ...

Gainers: Okta ( OKTA ) +13% . Kezar Life Sciences ( KZR ) +7% . Esperion Therapeutics. ( ESPR ) +6% . Syros Pharmaceuticals ( SYRS ) +5% . ImmunityBio ( IBRX ) +5% . Losers: Funko ( FNKO ) -27% . ZimVie  ( ZIMV ...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentations. ...

A positive difference in physical function in responders versus non-responders was noted The study indicates a favorable risk/benefit ratio and quality of life following N-803 plus BCG is comparable to BCG alone ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy ...

ImmunityBio ( NASDAQ: IBRX ) on Wednesday entered into a securities purchase agreement for a registered direct offering, providing for the issuance of common stock and warrants, for gross proceeds of $50 million. Shares -6.3% at $3.51. If fully exercised, the warrants...

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offerin...

Positive findings in third line and greater metastatic pancreatic cancer patients (N=83) with doubled median overall survival (OS) versus historical OS Median overall survival of 5.8 months and 61% of patients (51/83) exhibited disease control All treatments in an outpatient setting of co...